Top Gene Therapy Companies are opening new possibilities in medicine by finding smarter ways to treat diseases at their genetic source. Let’s take a look at the companies and breakthroughs making this possible.

Gene therapy is going to change the way doctors and patients perceive some of the most difficult diseases in the world, because through gene therapy, it is possible to cure genetic disease rather than just treating the symptoms of a condition. More and more scientists are investigating genes that cause diseases and developing means of correcting, replacing or modifying those genes. From fixing the genes to CRISPR technology, 2026 is bringing some truly revolutionary developments. In this Business Fortune article, we look at the Top Gene Therapy Companies, the technology they are developing, major breakthroughs in 2026, and what the future of gene therapy could look like.

What Is Gene Therapy and How Does It Work?

Gene therapy is a type of medical treatment that aims to change genetic information inside a patient’s cells to treat or prevent disease. The basic idea sounds simple but the science behind it is highly advanced than we could imagine.

Gene therapy treatment may involve introducing a new copy of the gene if the gene is absent or dysfunctional. Others use gene editing to change a specific part of DNA. In some cases, scientists use specially designed viruses to carry genetic material into cells. Other approaches use different delivery systems to reach the right tissue.

It is not theory alone. The U.S. Food and Drug Administration has a growing list of FDA-approved cellular and gene therapies, which include treatments for inherited disorders, blood disorders, some types of cancer, and skin conditions.

Five Leading Gene Therapy Companies to Watch in 2026

The gene therapy industry now includes major pharmaceutical companies as well as specialist biotechnology firms. Each is taking a different approach to solving one of medicine’s biggest challenge of safely delivering genetic treatments to the right cells.

Vertex Pharmaceuticals

Vertex Pharmaceuticals has been able to position itself as one of the most highly-regarded companies in the field of genetics through its research on Casgevy, which is a CRISPR drug that is a product of collaboration between Vertex Pharmaceuticals and CRISPR Therapeutics. This CRISPR drug utilizes gene editing on the patient's blood stem cells.

A major 2026 development came in July, when the FDA expanded Casgevy’s approval to patients as young as two years old with sickle cell disease or transfusion-dependent beta-thalassemia. This made it the first gene therapy approved for children aged two and older with sickle cell disease.

Novartis

For several years now, Novartis has had a significant contribution in the field of gene therapies. Among the gene therapies from Novartis is the treatment called Zolgensma that addresses the problem of spinal muscular atrophy, which is a genetic disease affecting motor neurons. Another gene therapy from Novartis is Itvisma, also included in the FDA list of gene therapies.

The importance of big pharmaceutical firms in the field of gene therapy can be seen through Novartis. Scientific development is not the only issue that needs to be dealt with; manufacturing, distribution, and treatment are also significant.

Sarepta Therapeutics

Sarepta’s reputation is based on its ability to develop gene medicines that help treat rare disorders, including Duchenne muscular dystrophy. The firm’s Elevidys is a type of gene therapy that is intended to deliver the shorter version of the dystrophin gene in order to treat the genetic cause of Duchenne. As of 2026, the company has provided more data about functional benefits of the therapy in ambulatory adults.

Earlier this year, data from the EMBARK study after three years revealed reduced disease progression on several important measures of motor function compared to an external control group. The company also commercialized Elevidys in Japan in 2026, becoming the first ever gene therapy to be marketed in Japan for Duchenne muscular dystrophy.

Intellia Therapeutics

Intellia is one of those companies working towards the future of gene therapy technology that involves the application of CRISPR gene editing in vivo. This is different from gene therapies that take cells out of the body, edit them in the lab, and insert them back into the body.

In 2026, Intellia reported positive Phase 3 results for lonvoguran ziclumeran, or lonvo-z, in hereditary angioedema. The company said a single dose reduced attacks and that it had begun a rolling application process with the FDA. The development is important because it could move gene editing closer to a simple one-time treatment model for some diseases.

Krystal Biotech

Krystal Biotech is an example of companies that are proving that gene therapy need not always be limited to disorders of blood or muscles. One of its products is the Vyjuvek treatment which is used to treat dystrophic epidermolysis bullosa, a very rare skin genetic disorder.

The UK approved Vyjuvek for use by those with the disease since birth in May 2026. The company claimed that this was the first time that a genetic medicine had been approved for dystrophic epidermolysis bullosa. This is a good example of how gene therapy technology has expanded to other parts of the body.

Other Gene Therapy Biotech Companies

The industry is much larger than a few major names. Companies such as bluebird bio, Spark Therapeutics, BioMarin, Rocket Pharmaceuticals, Ultragenyx and other specialist developers have contributed to the growing list of genetic medicines.

The U.S Food and Drug Administration approved product list includes therapies such as Lyfgenia from bluebird bio, Luxturna from Spark Therapeutics, Hemgenix from CSL Behring, Kresladi from Rocket Pharmaceuticals and several other products.

This broad group of gene therapy biotech companies is important because rare diseases often require highly specialized research. Smaller biotechnology companies can focus heavily on one disease area while larger pharmaceutical companies can provide the resources needed for late-stage development and global commercialization.

How Are Gene Therapy Companies Advancing Medicine?

The most significant development is the move from symptom treatment to genetic-based disease treatment.

There have been many advancements in gene therapy techniques. Some therapies involve the replacement of a defective gene. Other treatments involve making alterations to DNA, while some add genetic instructions which allow cells to synthesize certain proteins. Researchers have also been developing delivery mechanisms to ensure the treatments get to organs such as the liver, brain, eyes, and muscles.

CRISPR is another major advancement in genetic therapy research. CRISPR technology involves altering DNA in a highly specific manner, which has helped in the treatment of diseases which were almost impossible to treat in the past.

The other major development is personalized medicine, where in the future, treatments will be based on a patient’s specific genetic disorder.

What Are the Latest Gene Therapy Breakthroughs?

One of the clearest breakthroughs in 2026 is the progress of in vivo gene editing. Intellia's Phase 3 results for lonvo-z marked a major step for CRISPR-based treatment delivered directly inside the body. Nature Biotechnology described it as the first Phase 3 result for an in vivo gene editor.

Another important development is the expansion of access to existing therapies. Casgevy's 2026 approval for younger children shows how an established genetic medicine can move into new patient groups.

The field is also becoming more diverse. By 2026, more than 50 gene therapies had received approval globally, according to a Nature Medicine editorial. At the same time, the publication highlighted challenges around safety, manufacturing costs and access.

So, it's not just a matter of gaining more approvals. The aim is to make them safer, easier to produce, and available to more patients.

How Effective Is Gene Therapy?

Gene therapy consists of different forms of treatments therefore, its efficiency depends on such factors like the type of disease, therapy, and patient's health.

There have been some therapies that have shown some good results, such as some therapies for some eye-related genetic problems, Spinal Muscular Atrophy, blood problems, and other rare conditions. But still, gene therapy does not automatically mean that the patient will be cured.

Follow-up of the patient for some more time is very much required. It is necessary to know how long the effects last and whether another session of the therapy will be required after some years, and about some other side effects that may occur.

The Challenges Behind Gene Therapy Treatments

The science may be outstanding, but there are other things involved in developing a gene therapy for patients. For example, one of the biggest obstacles may be production. Such therapies may need elaborate techniques and special facilities. The development process may be very costly, resulting in an expensive product at the end.

There are safety concerns as well. It may be difficult for the body to accept the delivery system used and modifying genetic code always needs to be done carefully. Recent events within the industry have shown scientists that promising technology needs to undergo rigorous safety trials as well. Nature Medicine stated that safety issues and high manufacturing costs are major problems in this industry.

Also, the accessibility is one more challenge. A therapy may prove its efficiency during the trial stage but fail in delivering it to patients due to other reasons.

The Future of Gene Therapy

The future of gene therapy is likely to focus on making treatments more precise, safer and easier to deliver. The best gene therapy companies will therefore not necessarily be those with the most products. They will be the companies that can turn promising genetic science into treatments that are safe, practical and genuinely useful for patients.

As 2026 continues, gene therapy is moving from an experimental idea toward a more established part of modern medicine. The next stage could be even more significant as gene editing becomes more targeted and personalized.

FAQs

What diseases can gene therapy treat?

Gene therapy can treat certain inherited and rare diseases, including some blood disorders, spinal muscular atrophy, inherited vision loss, Duchenne muscular dystrophy and genetic skin disorders. Researchers are also testing gene-based treatments for many other conditions.

Which companies lead gene therapy?

Leading companies include Vertex Pharmaceuticals, Novartis, Sarepta Therapeutics, Intellia Therapeutics, Krystal Biotech, bluebird bio, Spark Therapeutics and other specialist biotechnology companies. Their programs cover different diseases and technologies.

Is gene therapy a permanent cure?

Some gene therapies are designed as one-time treatments and can provide long-lasting benefits, but that does not mean every gene therapy permanently cures a disease. Long-term studies are needed to understand how durable each treatment is.

What makes CRISPR different from traditional gene therapy?

Traditional gene therapy often adds genetic material to cells. CRISPR can make targeted changes to DNA. This gives researchers another way to address genetic problems and has opened new possibilities for treating disease.

Will gene therapy become more common in the future?

It is likely to become more widely used as researchers improve safety, delivery, manufacturing and access. The growing number of approved therapies and advanced clinical trials suggests that genetic medicine will play an increasingly important role in healthcare.